UK markets close in 2 hours 46 minutes

AstraZeneca PLC (AZN.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
11,922.00+570.00 (+5.02%)
As of 01:29PM BST. Market open.
Full screen
Previous close11,352.00
Open11,890.00
Bid11,924.00 x 0
Ask11,928.00 x 0
Day's range11,790.00 - 12,086.00
52-week range9,461.00 - 12,186.00
Volume1,210,453
Avg. volume2,911,904
Market cap184.817B
Beta (5Y monthly)0.19
PE ratio (TTM)38.83
EPS (TTM)3.07
Earnings date25 Apr 2024
Forward dividend & yield2.28 (2.01%)
Ex-dividend date22 Feb 2024
1y target est125.31
  • Yahoo Finance Video

    Alphabet, Microsoft, Southwest earnings: What to watch

    Here are some of the biggest stories investors will be watching on Thursday, April 25, 2024. A slew of companies will report their quarterly results including Microsoft (MSFT), Alphabet (GOOG, GOOGL), and Southwest Airlines (LUV). On the economic data front, the highly anticipated preliminary read on first quarter GDP will be released. Economists are expecting that the US economy grew by 2.2% in the first three months of the year. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith

  • PA Media: Money

    Cancer drugs help drive AstraZeneca sales sharply higher

    Shares in the Cambridge-based company jumped by 5% in early trading.

  • PR Newswire

    AbelZeta Announces Abstract for C-CAR031 Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

    AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual M